Comparison · NCT05701007-deaths
Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: deaths from any cause. Trial comparisons, record NCT05701007-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05701007-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.431 | 0.397 | 0.466 | wilson | |
| Risk in group 2 | 0.391 | 0.351 | 0.432 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0408 | -0.0126 | 0.0934 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.969 | 1.26 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.949 | 1.48 | log | |
| Number needed to harm, for one more death from any cause on Participants Diagnosed With mCSPC than on Participants Diagnosed With mCRPC | 24.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Participants Diagnosed With mCSPC | Eligible participants with mCSPC and whose data were evaluated retrospectively. | 343 | 795 | EG000 |
| Group 2 | Participants Diagnosed With mCRPC | Eligible participants with mCRPC and whose data were evaluated retrospectively. | 218 | 558 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- NCT number
- NCT05701007
- Phases
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin
- Lead sponsor
- Pfizer
- Results first posted
- 2026-01-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05701007?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05701007-deaths